

BIOLASE TECHNOLOGY INC
Form 8-K
August 14, 2003

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

August 7, 2003 (Date of earliest event reported)

Commission File Number 000-19627

BIOLASE TECHNOLOGY, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware
*(State or Other Jurisdiction of Incorporation
or Organization)*

000-19627
*(Commission file
number)*

87-0442441
(I.R.S. Employer Identification No.)

Edgar Filing: BIOLASE TECHNOLOGY INC - Form 8-K

981 Calle Amanecer

San Clemente, California 92673

(Address of Principal Executive Offices, Including Zip Code)

(949) 361-1200

(Registrant's Telephone Number, Including Area Code)

Item 7. Financial Statements and Exhibits.

(c) Exhibits.

99.1 Press Release, dated August 7, 2003.

Item 12. Results of Operations and Financial Condition.

On August 7, 2003, BioLase Technology, Inc. issued a press release announcing that it and its independent accountants have decided to seek guidance from the Securities and Exchange Commission regarding the accounting affect of certain language in the BioLase's purchase order forms. A copy of the press release is attached herewith as Exhibit 99.1.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: August 13, 2003

BIOLASE TECHNOLOGY, INC.,

(Registrant)

By:

/s/ EDSON J. ROOD

Edson J. Rood

Vice President and

Chief Financial Officer

(Principal Financial and

Accounting Officer)